Millennium Management LLC Purchases Shares of 447,237 Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Millennium Management LLC purchased a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 447,237 shares of the biopharmaceutical company's stock, valued at approximately $3,819,000. Millennium Management LLC owned approximately 0.28% of Ocular Therapeutix as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of OCUL. MetLife Investment Management LLC increased its position in shares of Ocular Therapeutix by 2.7% in the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock valued at $792,000 after acquiring an additional 2,454 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Ocular Therapeutix by 10.0% in the 4th quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company's stock valued at $237,000 after acquiring an additional 2,526 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Ocular Therapeutix by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock worth $755,000 after acquiring an additional 2,853 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock worth $285,000 after purchasing an additional 3,347 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of Ocular Therapeutix by 0.6% during the fourth quarter. Cetera Investment Advisers now owns 723,840 shares of the biopharmaceutical company's stock worth $6,182,000 after purchasing an additional 4,342 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Insider Transactions at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Pravin Dugel sold 21,219 shares of the company's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the sale, the insider now owns 3,499,099 shares of the company's stock, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,079 shares of company stock valued at $208,739. Corporate insiders own 2.30% of the company's stock.

Analysts Set New Price Targets

OCUL has been the topic of several analyst reports. William Blair assumed coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating on the stock. JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. Finally, Needham & Company LLC dropped their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.25.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded up $0.22 during midday trading on Tuesday, reaching $8.33. The company had a trading volume of 2,951,070 shares, compared to its average volume of 1,406,612. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78. The company has a market capitalization of $1.33 billion, a P/E ratio of -6.31 and a beta of 1.51. The firm's fifty day simple moving average is $7.39 and its 200-day simple moving average is $7.89.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. As a group, equities analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.